```json
{
"content": [
{
"type": "paragraph",
"content": "The Biopharmaceutical CDMO industry trends over the past 18 months have been defined by aggressive capacity build-outs and strategic consolidation. Thermo Fisher’s $18.5 billion buyout of PPD closed in late 2022, instantly fusing late-stage CRO databases with commercial-scale biologics manufacturing to create end-to-end \"make-test\" bundles for sponsors. Catalent’s $2.8 billion acquisition of Bristol Myers Squibb’s sterile injectable plant in Anagni (closed Q1 2023) is now repurposed for high-potency antibody-drug conjugates, adding 120k L of microbial capacity that is already 70% booked through 2026. Samsung Biologos and SK Pharmteco have each announced $1 billion expansions in Incheon and Songdo, respectively, to capture the surge in multi-specific antibody and mRNA programs that prefer dual-sourcing outside China."
},
{
"type": "paragraph",
"content": "Technology launches are equally transformative: WuXi STA debuted its WuXiUP continuous bioprocessing platform that trims perfusion timelines by 40%, while Lonza launched the GS piggyBac system for stable 20 g/L titers without methotrexate amplification. Regulatory tailwinds arrived when the FDA finalized its guidance on Quality by Design for post-approval changes in April 2023, giving CDMOs a clear pathway to implement single-use retrofits without new BLA supplements—lowering validation costs by up to 30%."
},
{
"type": "paragraph",
content: "Venture funding is flowing into modality-specific specialists: AGC Biologica closed a $250 million Series C to scale microbial-based AAV production, and CDMO-as-a-Service start-up Resilience added another $410 million to bring its Series D total to $1 billion, betting on decentralized, AI-driven manufacturing clouds. Enterprise buyers increasingly prioritize resilience over price, pushing long-term, capacity-reserve contracts from 35% to 58% of new deals. Looking ahead, expect a wave of carve-outs as Big Pharma sheds legacy small-molecule sites, and CDMOs race to integrate AI process analytics to guarantee real-time release, turning today’s capacity arms race into tomorrow’s data-driven moat."
}
]
}
```
